BIOTHEUS
LIVE

Serial Number

79344182

Owner

Biotheus Inc.

Attorney

Michael T. Smith

Filing Date

Apr 14, 2022

Add to watchlist:

No watchlists yet
View on USPTO

BIOTHEUS Trademark

Serial Number: 79344182 • Registration: 7209518

BIOTHEUS is a trademark filed by Biotheus Inc. on April 14, 2022. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

Biotheus Inc.

10B, Building 4, No. 1 Keji 7th Road,
Zhuhai, Guangdong 519080 , CN

Entity Type: 03

BioNTech (Zhuhai) Pharmaceuticals R&D Co., Ltd.

10B, Building 4, No. 1 Keji 7th Road,

Entity Type: 98

Trademark Details

Filing Date

April 14, 2022

Registration Date

November 7, 2023

Published for Opposition

August 22, 2023

Goods & Services

Medicines used for treating cancers; biological preparations used for treating cancer; anti-cancer pharmaceutical preparations; medicines for human purposes for the treatment of cancer, immune function affection, nervous system diseases, respiratory system diseases, hematological system diseases, circulatory system diseases, hypertensive diseases, diabetic diseases, digestive system diseases, bone and joint diseases, endocrine and metabolic system diseases, ankylosing spondylitis disease, psoriasis, lupus erythematosus disease, rheumatoid arthritis diseases, immunomodulatory diseases, urinary system diseases, skin system diseases, reproductive system diseases; pharmaceutical preparations for the treatment of cancer, immune function affection, nervous system diseases, respiratory system diseases, hematological system diseases, circulatory system diseases, hypertensive diseases, diabetic diseases, digestive system diseases, bone and joint diseases, endocrine and metabolic system diseases, ankylosing spondylitis disease, psoriasis, lupus erythematosus disease, rheumatoid arthritis diseases, immunomodulatory diseases, urinary system diseases, skin system diseases, reproductive system diseases; chemico-pharmaceutical preparations for the treatment of cancer, immune function affection, nervous system diseases, respiratory system diseases, hematological system diseases, circulatory system diseases, hypertensive diseases, diabetic diseases, digestive system diseases, bone and joint diseases, endocrine and metabolic system diseases, ankylosing spondylitis disease, psoriasis, lupus erythematosus disease, rheumatoid arthritis diseases, immunomodulatory diseases, urinary system diseases, skin system diseases, reproductive system diseases; medicines for medical purposes for the treatment of cancer, immune function affection, nervous system diseases, respiratory system diseases, hematological system diseases, circulatory system diseases, hypertensive diseases, diabetic diseases, digestive system diseases, bone and joint diseases, endocrine and metabolic system diseases, ankylosing spondylitis disease, psoriasis, lupus erythematosus disease, rheumatoid arthritis diseases, immunomodulatory diseases, urinary system diseases, skin system diseases, reproductive system diseases; chemical preparations for pharmaceutical purposes for the treatment of cancer, immune function affection, nervous system diseases, respiratory system diseases, hematological system diseases, circulatory system diseases, hypertensive diseases, diabetic diseases, digestive system diseases, bone and joint diseases, endocrine and metabolic system diseases, ankylosing spondylitis disease, psoriasis, lupus erythematosus disease, rheumatoid arthritis diseases, immunomodulatory diseases, urinary system diseases, skin system diseases, reproductive system diseases; biological preparations for medical purposes for the treatment of cancer, immune function affection, nervous system diseases, respiratory system diseases, hematological system diseases, circulatory system diseases, hypertensive diseases, diabetic diseases, digestive system diseases, bone and joint diseases, endocrine and metabolic system diseases, ankylosing spondylitis disease, psoriasis, lupus erythematosus disease, rheumatoid arthritis diseases, immunomodulatory diseases, urinary system diseases, skin system diseases, reproductive system diseases; biochemicial medicines for the treatment of cancer, immune function affection, nervous system diseases, respiratory system diseases, hematological system diseases, circulatory system diseases, hypertensive diseases, diabetic diseases, digestive system diseases, bone and joint diseases, endocrine and metabolic system diseases, ankylosing spondylitis disease, psoriasis, lupus erythematosus disease, rheumatoid arthritis diseases, immunomodulatory diseases, urinary system diseases, skin system diseases, reproductive system diseases; medicines in the form of injections for the treatment of cancer, immune function affection, nervous system diseases, respiratory system diseases, hematological system diseases, circulatory system diseases, hypertensive diseases, diabetic diseases, digestive system diseases, bone and joint diseases, endocrine and metabolic system diseases, ankylosing spondylitis disease, psoriasis, lupus erythematosus disease, rheumatoid arthritis diseases, immunomodulatory diseases, urinary system diseases, skin system diseases, reproductive system diseases

Scientific research in the field of medication evaluation; quality control evaluation for others; scientific research in the nature of conducting clinical trials for others; scientific research in the field of antibody; services of medical laboratory

Filing History

CHANGE OF NAME/ADDRESS REC'D FROM IB
Jun 25, 2026 ADCH
FINAL DECISION TRANSACTION PROCESSED BY IB
Mar 4, 2024 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Feb 8, 2024 FICS
FINAL DISPOSITION PROCESSED
Feb 8, 2024 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Feb 7, 2024 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Nov 7, 2023 NRCC
REGISTERED-PRINCIPAL REGISTER
Nov 7, 2023 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Aug 22, 2023 NPUB
PUBLISHED FOR OPPOSITION
Aug 22, 2023 PUBO
NOTIFICATION PROCESSED BY IB
Aug 21, 2023 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Aug 2, 2023 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Aug 2, 2023 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Aug 2, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 14, 2023 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 13, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 13, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 13, 2023 TROA
REFUSAL PROCESSED BY IB
Apr 19, 2023 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Mar 30, 2023 RFCS
REFUSAL PROCESSED BY MPU
Mar 30, 2023 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Feb 8, 2023 RFCR
NON-FINAL ACTION WRITTEN
Feb 7, 2023 CNRT
ASSIGNED TO EXAMINER
Feb 1, 2023 DOCK
NEW REPRESENTATIVE AT IB RECEIVED
Sep 10, 2022 NREP
APPLICATION FILING RECEIPT MAILED
Jul 12, 2022 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 8, 2022 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jul 7, 2022 REPR